Publication:
Mortality according to treatment in metastatic collecting duct renal cell carcinoma

dc.contributor.coauthorPanunzio, Andrea
dc.contributor.coauthorSorce, Gabriele
dc.contributor.coauthorTappero, Stefano
dc.contributor.coauthorHohenhorst, Lukas
dc.contributor.coauthorGarcia, Cristina Cano
dc.contributor.coauthorPiccinelli, Mattia
dc.contributor.coauthorTian, Zhe
dc.contributor.coauthorTafuri, Alessandro
dc.contributor.coauthorDe Cobelli, Ottavio
dc.contributor.coauthorChun, Felix K. H.
dc.contributor.coauthorTilki, Derya
dc.contributor.coauthorTerrone, Carlo
dc.contributor.coauthorBriganti, Alberto
dc.contributor.coauthorKapoor, Anil
dc.contributor.coauthorSaad, Fred
dc.contributor.coauthorShariat, Shahrokh F.
dc.contributor.coauthorCerruto, Maria Angela
dc.contributor.coauthorAntonelli, Alessandro
dc.contributor.coauthorKarakiewicz, Pierre I.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorTilki, Derya
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:40:49Z
dc.date.issued2023
dc.description.abstractLarge-scale, contemporary, controlled analysis of mortality in metastatic collecting duct renal carcinoma are scarce. Moreover, the optimal management of these patients is unknown. Within the SEER, 155 metastatic collecting duct renal carcinoma patients were identified. Despite the aggressive behavior and dismal survival prognosis, combination of cytoreductive nephrectomy and systemic therapy provide the lowest mortality rates. Introduction: Controlled contemporary analyses of mortality in metastatic collecting duct renal cell carcinoma (mcdRCC) are unavailable. We addressed this knowledge gap and tested rates of treatment and associated mortal-ity in patients with mcdRCC. Patients and Methods: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 155 mcdRCC patients. Kaplan-Meier plots and Cox proportional hazards regression models tested the effect of treatment (cytoreductive nephrectomy [CN] alone vs. systemic therapy [ST] alone vs. combination of both CN + ST) on overall mortality (OM). Results: In the overall cohort (n = 155), 57 patients (37%) were treated with combination of both CN + ST, 46 (30%) underwent CN alone, 28 (18%) received ST alone, and 24 (15%) had none/unknown treatment. According to age categories (<= 59 vs. 60-69 vs. > 70 years), rates of combination of both CN + ST were 45% vs. 45% vs. 14%, respectively. CN alone was the most frequent type of treatment in patients aged > 70 (50%). Median overall survival was 4.0 months for CN alone vs. 5.5 months for ST alone vs. 9.0 months for combination of both CN + ST. In multivariable Cox regression models, where CN alone was the referent, the use of ST alone and combination of both CN + ST were respectively associated with a HR of 0.74 ( P = .3) and 0.43 ( P < .001), after adjustment for all covariates. Conclusions: In mcdRCC patients, concomitant use of CN and ST results in lowest mortality, followed by ST alone, and CN alone. In consequence combination of both CN + ST should be recommended whenever applicable.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume21
dc.identifier.doi10.1016/j.clgc.2022.08.010
dc.identifier.eissn1938-0682
dc.identifier.issn1558-7673
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85138182230
dc.identifier.urihttps://doi.org/10.1016/j.clgc.2022.08.010
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23452
dc.identifier.wos965091000001
dc.keywordsCollecting duct carcinoma
dc.keywordsRCC
dc.keywordsVariant histology
dc.keywordsOverall mortality
dc.keywordsSEER
dc.language.isoeng
dc.publisherCIG Media Group, Lp
dc.relation.ispartofClinical Genitourinary Cancer
dc.subjectOncology
dc.subjectUrology
dc.subjectNephrology
dc.titleMortality according to treatment in metastatic collecting duct renal cell carcinoma
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorTilki, Derya
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files